REG - Creo Medical Group - Posting of Annual Report and Notice of AGM

Creo MedicalAnnouncement

26/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230526:nRSZ6944Aa&default-theme=true

RNS Number : 6944A  Creo Medical Group PLC  26 May 2023

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Posting of 2022 Annual Report and Accounts

Notice of Annual General Meeting

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of surgical endoscopy, announces that the Annual Report and
Accounts for the year ended 31 December 2022 ("2022 Annual Report") and the
Notice of the Company's Annual General Meeting ("AGM") have now been published
on the Company's website
at https://creomedical.com/investors/reports-and-presentations/
(https://creomedical.com/investors/reports-and-presentations/) , with hard
copies being posted to those shareholders who have not elected to receive
electronic communication from the Company.

 

The AGM will be held on Tuesday, 27 June 2023 at 10:00am at the offices of
Osborne Clarke, Halo, Counterslip, Bristol BS1 6AJ and will consider the
Resolutions set out in the Notice of AGM. The Company's CEO, Craig Gulliford,
will make a short presentation at the meeting. No new material information
will be included within the presentation.

 

Shareholders are encouraged to vote by proxy at the AGM, which can be done:

 

·    By completing, signing the Form of Proxy and returning it to
Equiniti; or

·    In the case of CREST members, by utilising the CREST electronic proxy
appointment service.

 

Proxy votes must be received no later than 10:00am on 23 June 2023.
Shareholders are recommended to appoint the Chair of the meeting as their
proxy rather than a named person, as any such other person may not be
permitted to attend the AGM in the event of unforeseen circumstances (e.g.
illness).

 

Voting will be conducted on each Resolution by way of a poll.

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cenkos Securities plc                              +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Sales)

 Numis Securities Limited (Joint Broker)            +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                         Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.  CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAAAMTTMTATBAJ